WO2014064715A3 - Forme amorphe de chlorhydrate de vilazodone et son procédé de préparation - Google Patents

Forme amorphe de chlorhydrate de vilazodone et son procédé de préparation Download PDF

Info

Publication number
WO2014064715A3
WO2014064715A3 PCT/IN2013/000643 IN2013000643W WO2014064715A3 WO 2014064715 A3 WO2014064715 A3 WO 2014064715A3 IN 2013000643 W IN2013000643 W IN 2013000643W WO 2014064715 A3 WO2014064715 A3 WO 2014064715A3
Authority
WO
WIPO (PCT)
Prior art keywords
vilazodone hydrochloride
amorphous form
preparing
processes
preparation
Prior art date
Application number
PCT/IN2013/000643
Other languages
English (en)
Other versions
WO2014064715A2 (fr
Inventor
Shri Prakash Dhar Dwivedi
Ramesh Chandra SINGH
Kishorkumar Maneklal Vinchhi
Sachin Ashokrao PATIL
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2014064715A2 publication Critical patent/WO2014064715A2/fr
Publication of WO2014064715A3 publication Critical patent/WO2014064715A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme amorphe de chlorhydrate de vilazodone et des procédés pour la préparation de la forme amorphe de chlorhydrate de vilazodone. La présente invention concerne également des compositions pharmaceutiques qui comprennent une quantité thérapeutiquement efficace de la forme amorphe de chlorhydrate de vilazodone et l'utilisation desdites compositions pour le traitement d'un trouble dépressif majeur (MDD).
PCT/IN2013/000643 2012-10-22 2013-10-21 Forme amorphe de chlorhydrate de vilazodone et son procédé de préparation WO2014064715A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3075MU2012 2012-10-22
IN3075/MUM/2012 2012-10-22

Publications (2)

Publication Number Publication Date
WO2014064715A2 WO2014064715A2 (fr) 2014-05-01
WO2014064715A3 true WO2014064715A3 (fr) 2014-09-12

Family

ID=49917688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000643 WO2014064715A2 (fr) 2012-10-22 2013-10-21 Forme amorphe de chlorhydrate de vilazodone et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2014064715A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861586A4 (fr) 2012-06-13 2015-11-11 Apotex Inc Formes de vilazodone et procédés de préparation associés
CN105601536B (zh) * 2014-11-19 2017-10-13 北京凯莱天成医药科技有限公司 一种维拉佐酮中间体的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738722A1 (fr) * 1995-04-20 1996-10-23 MERCK PATENT GmbH Dérivés d'acides 5-amino-benzofuran-2-carboxyliques
WO2006114202A1 (fr) * 2005-04-26 2006-11-02 Merck Patent Gmbh Procede de production de 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide
WO2012131706A1 (fr) * 2011-03-20 2012-10-04 Cadila Healthcare Limited Forme amorphe du chlorhydrate de vilazodone et son procédé de préparation
WO2013078361A1 (fr) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Formes à l'état solide de vilazodone et de chlorhydrate de vilazodone
WO2013114338A1 (fr) * 2012-02-01 2013-08-08 Ranbaxy Laboratories Limited Procédé pour la préparation de vilazodone ou de ses sels pharmaceutiquement acceptables
WO2013168126A1 (fr) * 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Formes cristallines du chlorhydrate de vilazodone et de la base libre de la vilazodone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738722A1 (fr) * 1995-04-20 1996-10-23 MERCK PATENT GmbH Dérivés d'acides 5-amino-benzofuran-2-carboxyliques
WO2006114202A1 (fr) * 2005-04-26 2006-11-02 Merck Patent Gmbh Procede de production de 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide
WO2012131706A1 (fr) * 2011-03-20 2012-10-04 Cadila Healthcare Limited Forme amorphe du chlorhydrate de vilazodone et son procédé de préparation
WO2013078361A1 (fr) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Formes à l'état solide de vilazodone et de chlorhydrate de vilazodone
WO2013114338A1 (fr) * 2012-02-01 2013-08-08 Ranbaxy Laboratories Limited Procédé pour la préparation de vilazodone ou de ses sels pharmaceutiquement acceptables
WO2013168126A1 (fr) * 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Formes cristallines du chlorhydrate de vilazodone et de la base libre de la vilazodone

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHENG QING-FANG ET AL: "Improved method for synthesis of vilazodone hydrochloride", ZHONGGUO XIN YAO ZAZHI - CHINESE NEW DRUGS JOURNAL, GAI-KAN BIANJIBU, BEIJING, CN, vol. 22, no. 2, 2013, pages 226 - 229, XP008168739, ISSN: 1003-3734 *
DATABASE HCAPLUS [online] ACS; XP002723645, retrieved from STN Database accession no. 159:357783 (DN) *
DATABASE HCAPLUS [online] ACS; XP002723646, retrieved from STN Database accession no. 159:221109 (DN) *
K. NAGAPUDI ET AL: "Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Preparation, Characterization, and Formulation", CURRENT BIOACTIVE COMPOUNDS, vol. 4, 2008, pages 213 - 224, XP055078333 *
WANG QIFA ET AL: "Synthesis of Vilazodone Hydrochloride", ZHONGGUO YIYAO GONGYE ZAZHI - CHINESE JOURNAL OF PHARMACEUTICALS, SHANGHAI YIYAO GONGYE YANJIUYUAN, SHANGHAI, CN, vol. 44, no. 1, 2013, pages 3 - 5,12, XP008168740, ISSN: 1001-8255 *

Also Published As

Publication number Publication date
WO2014064715A2 (fr) 2014-05-01

Similar Documents

Publication Publication Date Title
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MD20150091A2 (ro) Compuşi antivirali
WO2012168431A3 (fr) Polypeptides
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
WO2013109972A3 (fr) Composés thérapeutiques
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
WO2013181339A3 (fr) Analogues de cyclosporine a
WO2014036502A3 (fr) Composés de tétracyclines
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12017500595B1 (en) Aldosterone synthase inhibitors
UA117154C2 (uk) Антагоністи s1p3
MX2013007661A (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
WO2014014794A3 (fr) Antagonistes des récepteurs aux minéralocorticoïdes
IN2013DN02555A (fr)
WO2014064715A3 (fr) Forme amorphe de chlorhydrate de vilazodone et son procédé de préparation
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
EP3484511A4 (fr) Compositions vaccinales pour le traitement d'une infection par le virus zika
WO2012122451A3 (fr) Polymorphes de maxacalcitol et procédé de préparation de maxacalcitol
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13817743

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13817743

Country of ref document: EP

Kind code of ref document: A2